+

WO2007039177A3 - Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques - Google Patents

Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques Download PDF

Info

Publication number
WO2007039177A3
WO2007039177A3 PCT/EP2006/009303 EP2006009303W WO2007039177A3 WO 2007039177 A3 WO2007039177 A3 WO 2007039177A3 EP 2006009303 W EP2006009303 W EP 2006009303W WO 2007039177 A3 WO2007039177 A3 WO 2007039177A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
phenyl
processes
pyridinyl
pharmaceuticals
Prior art date
Application number
PCT/EP2006/009303
Other languages
English (en)
Other versions
WO2007039177A2 (fr
WO2007039177B1 (fr
Inventor
Stefanie Keil
Matthias Urmann
Patrick Bernardelli
Maike Glien
Wolfgang Wendler
Karen Chandross
Lan Lee
Original Assignee
Sanofi Aventis
Stefanie Keil
Matthias Urmann
Patrick Bernardelli
Maike Glien
Wolfgang Wendler
Karen Chandross
Lan Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35788653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007039177(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP06792251.8A priority Critical patent/EP1931337B1/fr
Priority to JP2008532647A priority patent/JP2009509988A/ja
Priority to BRPI0617207-5A priority patent/BRPI0617207A2/pt
Priority to NZ566877A priority patent/NZ566877A/en
Priority to AU2006299091A priority patent/AU2006299091A1/en
Application filed by Sanofi Aventis, Stefanie Keil, Matthias Urmann, Patrick Bernardelli, Maike Glien, Wolfgang Wendler, Karen Chandross, Lan Lee filed Critical Sanofi Aventis
Priority to CA002624102A priority patent/CA2624102A1/fr
Publication of WO2007039177A2 publication Critical patent/WO2007039177A2/fr
Publication of WO2007039177A3 publication Critical patent/WO2007039177A3/fr
Publication of WO2007039177B1 publication Critical patent/WO2007039177B1/fr
Priority to NO20081369A priority patent/NO20081369L/no
Priority to IL190231A priority patent/IL190231A0/en
Priority to US12/055,780 priority patent/US7709481B2/en
Priority to TNP2008000148A priority patent/TNSN08148A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'invention concerne des dérivés de phényl-1,2,4-oxadiazolone sous toutes leurs formes stéréoisomères et leurs mélanges dans des proportions quelconques, ainsi que les sels physiologiquement acceptables et les formes tautomères de deux-ci qui exercent une activité agoniste sur les récepteurs PPARΔ. L'invention décrit ainsi des composés représentés par la formule (I), dans laquelle les radicaux sont tels que définis dans la description, ainsi que les sels physiologiquement acceptables de ceux-ci et les procédés utilisés pour les obtenir. Ces composés sont utilisés pour traiter et/ou prévenir les troubles du métabolisme des acides gras, les troubles de l'utilisation du glucose, les troubles impliquant l'insulinorésistance et la démyélinisation, ainsi que d'autres troubles neurodégénératifs du système nerveux central et périphérique.
PCT/EP2006/009303 2005-09-29 2006-09-26 Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques WO2007039177A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002624102A CA2624102A1 (fr) 2005-09-29 2006-09-26 Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
JP2008532647A JP2009509988A (ja) 2005-09-29 2006-09-26 フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
BRPI0617207-5A BRPI0617207A2 (pt) 2005-09-29 2006-09-26 derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
NZ566877A NZ566877A (en) 2005-09-29 2006-09-26 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006299091A AU2006299091A1 (en) 2005-09-29 2006-09-26 Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP06792251.8A EP1931337B1 (fr) 2005-09-29 2006-09-26 Dérivés de phényle- et pyridinyle-1,2,4-oxadiazolone, procédés de leur préparation et leur utilisation comme produits pharmaceutiques
NO20081369A NO20081369L (no) 2005-09-29 2008-03-14 Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
IL190231A IL190231A0 (en) 2005-09-29 2008-03-17 Phenyl-and pyridinyl-1,2,4-oxadiazolone derivatives processes for their preparation and their use as pharmaceuticals
US12/055,780 US7709481B2 (en) 2005-09-29 2008-03-26 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals
TNP2008000148A TNSN08148A1 (en) 2005-09-29 2008-03-28 Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05021277 2005-09-29
EP05021277.8 2005-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/055,780 Continuation US7709481B2 (en) 2005-09-29 2008-03-26 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals

Publications (3)

Publication Number Publication Date
WO2007039177A2 WO2007039177A2 (fr) 2007-04-12
WO2007039177A3 true WO2007039177A3 (fr) 2007-09-07
WO2007039177B1 WO2007039177B1 (fr) 2007-11-01

Family

ID=35788653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009303 WO2007039177A2 (fr) 2005-09-29 2006-09-26 Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques

Country Status (23)

Country Link
US (1) US7709481B2 (fr)
EP (1) EP1931337B1 (fr)
JP (1) JP2009509988A (fr)
KR (1) KR20080048504A (fr)
CN (1) CN101272784A (fr)
AR (1) AR056095A1 (fr)
AU (1) AU2006299091A1 (fr)
BR (1) BRPI0617207A2 (fr)
CA (1) CA2624102A1 (fr)
CR (1) CR9785A (fr)
DO (1) DOP2006000203A (fr)
EC (1) ECSP088322A (fr)
IL (1) IL190231A0 (fr)
MA (1) MA29805B1 (fr)
NO (1) NO20081369L (fr)
NZ (1) NZ566877A (fr)
PE (1) PE20070620A1 (fr)
RU (1) RU2008112198A (fr)
TN (1) TNSN08148A1 (fr)
TW (1) TW200806658A (fr)
UY (1) UY29831A1 (fr)
WO (1) WO2007039177A2 (fr)
ZA (1) ZA200801629B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
CA2719507C (fr) * 2008-03-31 2018-03-27 Metabolex, Inc. Composes d'oxymethylene arylique et utilisations de ceux-ci
EP2334669B1 (fr) * 2008-10-01 2015-12-23 Bayer Intellectual Property GmbH Thiazoles substitués par un hétérocyclyle comme agent phytosanitaire
JP2012511525A (ja) 2008-12-11 2012-05-24 バイエル・クロップサイエンス・アーゲー 植物保護剤としてのチアゾリルオキシムエーテルおよびヒドラゾン
EP2198710A1 (fr) 2008-12-19 2010-06-23 Bayer CropScience AG Utilisation de 5-pyridine-4yl-(1,3)thiazoles destinés à lutter contre les champignons phytopathogènes
JP2012528847A (ja) * 2009-06-05 2012-11-15 ファイザー・インク Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
JP5960683B2 (ja) 2010-04-28 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺真菌剤としてのケトヘテロアリールピペリジンおよび−ピペラジン誘導体
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
CN106943407A (zh) 2010-07-26 2017-07-14 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
EP2532233A1 (fr) 2011-06-07 2012-12-12 Bayer CropScience AG Combinaisons de composés actifs
KR102098804B1 (ko) 2012-04-26 2020-04-08 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
KR20150003767A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 유도체
SG11201406733QA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
WO2000078313A1 (fr) * 1999-06-18 2000-12-28 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
WO2003015774A1 (fr) * 2001-08-17 2003-02-27 Astrazeneca Ab Composes exerçant une action sur la glucokinase
US6710063B1 (en) * 1999-06-25 2004-03-23 Smithkline Beecham Corporation Activators of PPAR delta
EP1424330A1 (fr) * 2001-08-10 2004-06-02 Nippon Chemiphar Co., Ltd. Activateur du recepteur delta sensible au proliferateur de peroxysome
EP1586573A1 (fr) * 2004-04-01 2005-10-19 Aventis Pharma Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
WO2005097762A2 (fr) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
WO1997040017A2 (fr) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulateurs de molecules possedant des unites de reconnaissance de la phosphotyrosine
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CA2318731C (fr) 1998-01-29 2012-05-29 Tularik Inc. Modulateurs du recepteur active de la proliferation des peroxysomes (ppar.gamma.)
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
CA2371308A1 (fr) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Derives d'acide tri-aryle en tant que ligands pour recepteur de peroxisome a activation par proliferateur (ppar)
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
WO2001016094A1 (fr) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Derives de sulfonylcarboxamide, leur procede de production et leur utilisation comme medicaments
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
MXPA02010746A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de la glucocinasa que contienen hidantoina.
MXPA02010745A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
KR100519826B1 (ko) 2000-05-08 2005-10-06 에프. 호프만-라 로슈 아게 파라-아민 치환된 페닐아미드 글루코키나제 활성화제
KR100556323B1 (ko) 2000-07-20 2006-03-03 에프. 호프만-라 로슈 아게 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
KR100545431B1 (ko) 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
DE10102322A1 (de) 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
EP1448538A1 (fr) 2001-11-15 2004-08-25 Eli Lilly And Company Agonistes de recepteurs alpha actives de la proliferation des peroxysomes
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
BR0215212A (pt) 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
CA2488161A1 (fr) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
EA011297B1 (ru) 2002-04-26 2009-02-27 Ф. Хоффманн-Ля Рош Аг Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
JPWO2003097824A1 (ja) 2002-05-16 2005-09-15 萬有製薬株式会社 グルコキナーゼタンパク質の結晶、及びその結晶を用いたドラッグデザイン方法
EP1531815B1 (fr) 2002-06-27 2014-09-24 Novo Nordisk A/S Activateurs de la glycokinase
CN1304371C (zh) 2002-07-12 2007-03-14 塞诺菲-安万特德国有限公司 杂环取代的苯甲酰脲、其药物和制备药物的用途
AU2003270285B2 (en) 2002-10-03 2007-04-26 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (GK) activators
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
WO2004063194A1 (fr) 2003-01-06 2004-07-29 Eli Lilly And Company Composes heteroaryle
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
TWI336329B (en) 2003-02-13 2011-01-21 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
DE10308356A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308354A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JPWO2004080943A1 (ja) 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
CA2520908A1 (fr) 2003-04-17 2004-11-04 Kalypsys, Inc. Composes aryle en tant que modulateurs de ppar et methodes de traitement des troubles metaboliques
CA2524436A1 (fr) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
EP1690538A4 (fr) 2003-12-02 2009-02-25 Shionogi & Co Derive d'isoxazole presentant un effet agoniste sur le recepteur active par les proliferateurs des peroxysomes
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
JP2007514794A (ja) 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
EP1699759B1 (fr) 2003-12-23 2010-10-20 AstraZeneca AB Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
EP1699760B1 (fr) 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Composes anti-hypercholesterolemie
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
AU2004309287B2 (en) 2003-12-29 2008-07-31 Banyu Pharmaceutical Co., Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
AU2004313246A1 (en) 2004-01-06 2005-07-28 Janssen Pharmaceutica, N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
AU2005209365A1 (en) 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
US20080312207A1 (en) 2004-02-18 2008-12-18 Craig Johnstone Compounds
AU2005214132B9 (en) 2004-02-18 2009-06-25 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
BRPI0508514A (pt) 2004-03-10 2007-08-14 Janssen Pharmaceutica Nv aril piperidinas ou piperazinas substituìdas por heterociclos de 5-membros inibidoras de mtp
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
CN1956984B (zh) 2004-04-01 2010-06-09 安万特药物公司 1,3,4-二唑-2-酮作为PPAR-δ调节剂
WO2005097738A1 (fr) 2004-04-06 2005-10-20 Dainippon Sumitomo Pharma Co., Ltd. Nouveau derive sulfonamide
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
CA2565211A1 (fr) 2004-04-29 2005-11-24 Abbott Laboratories Analogues d'amino-tetrazoles et methodes d'utilisation
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP1758611A2 (fr) 2004-06-17 2007-03-07 Novo Nordisk A/S Utilisation d'activateurs de glucokinase selectifs du foie
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
MX2007002689A (es) 2004-09-11 2007-05-16 Sanofi Aventis Deutschland 7-azaindoles y su uso como agonistas de ppar.
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
WO2000078313A1 (fr) * 1999-06-18 2000-12-28 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
US6710063B1 (en) * 1999-06-25 2004-03-23 Smithkline Beecham Corporation Activators of PPAR delta
EP1424330A1 (fr) * 2001-08-10 2004-06-02 Nippon Chemiphar Co., Ltd. Activateur du recepteur delta sensible au proliferateur de peroxysome
WO2003015774A1 (fr) * 2001-08-17 2003-02-27 Astrazeneca Ab Composes exerçant une action sur la glucokinase
EP1586573A1 (fr) * 2004-04-01 2005-10-19 Aventis Pharma Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
WO2005097762A2 (fr) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KULKARNI S S ET AL: "Three-Dimensional Quantitative Structure Activity Relationship (3-D-QSAR) of Antihyperglycemic Agents", 1999, BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, PAGE(S) 1475-1485, ISSN: 0968-0896, XP002345584 *

Also Published As

Publication number Publication date
UY29831A1 (es) 2007-04-30
CR9785A (es) 2008-05-21
JP2009509988A (ja) 2009-03-12
CA2624102A1 (fr) 2007-04-12
WO2007039177A2 (fr) 2007-04-12
NO20081369L (no) 2008-05-28
AU2006299091A1 (en) 2007-04-12
PE20070620A1 (es) 2007-07-10
DOP2006000203A (es) 2007-06-30
ECSP088322A (es) 2008-04-28
CN101272784A (zh) 2008-09-24
BRPI0617207A2 (pt) 2011-07-19
IL190231A0 (en) 2008-11-03
NZ566877A (en) 2010-05-28
ZA200801629B (en) 2009-03-25
EP1931337A2 (fr) 2008-06-18
KR20080048504A (ko) 2008-06-02
TNSN08148A1 (en) 2009-07-14
EP1931337B1 (fr) 2013-10-23
AR056095A1 (es) 2007-09-19
US20080261979A1 (en) 2008-10-23
RU2008112198A (ru) 2009-10-10
WO2007039177B1 (fr) 2007-11-01
US7709481B2 (en) 2010-05-04
TW200806658A (en) 2008-02-01
MA29805B1 (fr) 2008-09-01

Similar Documents

Publication Publication Date Title
WO2007039177A3 (fr) Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
WO2007039178A3 (fr) Derives de phenyl-[1,2,4]-oxadiazol-5-one a groupe phenyle : procedes de preparation et utilisation comme produits pharmaceutiques
TN2009000242A1 (en) Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
WO2007071963A3 (fr) Composes chimiques
TNSN06317A1 (en) Oxadiazolone derivatives as ppar delta agonists
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2009098715A3 (fr) Nouveaux dérivés de pyrazolo [3, 4 -d] pyrimidine en tant qu’agents anticancéreux
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2007039174A3 (fr) [1,3,4]-thiadiazol-2-yl-amides bicycliques de l'acide aryl-sulfonique, leurs procedes de preparation, et leur utilisation en tant que substances pharmaceutiques
TW200732328A (en) Derivatives of 2-aminothiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques
WO2007026254A3 (fr) Composes, leur preparation et leurs utilisations
TW200510399A (en) 1, 3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
TW200505830A (en) Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
MY140251A (en) Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals
TW200738654A (en) Alkoxymethyl-substituted benzoic acid derivatives, process for their preparation and their use as medicaments
WO2011015646A3 (fr) Dérivés de furane-imidazolone pour le traitement de maladies ou troubles cognitifs, neurodégénératifs ou neuronaux
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: CR2008-009785

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2008000122

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 12008500577

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006792251

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 190231

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 566877

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 0800725

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004051

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2624102

Country of ref document: CA

Ref document number: 1513/CHENP/2008

Country of ref document: IN

Ref document number: 1020087007393

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006299091

Country of ref document: AU

Ref document number: 200680035936.1

Country of ref document: CN

Ref document number: 2008532647

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008030545

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006299091

Country of ref document: AU

Date of ref document: 20060926

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006299091

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06792251

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006792251

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0617207

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080331

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载